DeCure for Epidermolysis bullosa simplex 5A, Ogna type
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for epidermolysis bullosa simplex 5A, Ogna type — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpidermolysis bullosa simplex 5A, Ogna type maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epidermolysis bullosa simplex 5a, ogna type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
plectin (PLEC) — PLEC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5J1I · 2.801 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Epidermolysis bullosa simplex is one subtype within a group of rare genetic disorders caused by mutations in at least 14 genes, leading to skin that blisters or tears from minor mechanical friction or trauma. The Ogna type is a specific variant of epidermolysis bullosa simplex. A 2022 review states the condition is autosomal dominant and that prevention begins with family and patient education, with infants requiring greater environmental control. Every individual receives a treatment plan tailored to the severity and extent of skin involvement. No drug therapy is described as standard or disease-modifying for this subtype in that review.
A 2010 review of inherited epidermolysis bullosa reported that cell and animal models had been used to test gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen, and that clinical trials for these approaches were being pursued in humans. That review did not report results from those trials. A 2024 scoping review of oral soft tissue lesions in children and adolescents with epidermolysis bullosa identified therapeutic strategies including laser photobiomodulation, topical corticosteroids, chlorhexidine, anaesthetic ointments, and vitamin supplementation, but noted that gaps remain in the standardisation of clinical protocols and in long-term evaluation. No controlled studies were cited that demonstrate efficacy of any drug for epidermolysis bullosa simplex, Ogna type.
A 2018 case report describes a 23-year-old woman with progressive dysphagia as an atypical presentation of epidermolysis bullosa, but provides no treatment outcome data. The 2024 review concludes that controlled studies are needed to support evidence-based clinical guidelines. What is still missing are controlled clinical trials specific to epidermolysis bullosa simplex, Ogna type, standardised outcome measures, and funding for long-term evaluation of any intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2010 · 54 citations
Inherited epidermolysis bullosa: recent basic and clinical advances
AbstractPURPOSE OF REVIEW: This review highlights key findings, both clinical and basic, that have been published in the field of inherited epidermolysis bullosa within the past few years. RECENT FINDINGS: New epidermolysis bullosa phenotypes, genotypes and modes of transmission have been identified, resulting in a revised classification system. Detailed evidence-based data are now available on the risk of extracutaneous complications in each of the major epidermolysis bullosa subtypes. Studies are now underway to try to better explain the biological aggressiveness of squamous cell carcinomas arising in epidermolysis bullosa skin. Cell and animal models have been refined and used to ascertain the feasibility of gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen. As a result, clinical trials are now being pursued to test each of these in humans. SUMMARY: Epidermolysis bullosa is caused by mutations in at least 14 genes, leading to a broad spectrum of entities, each of which has its own relative risk for the development of specific extracutaneous complications and/or premature death. Intensive research, both basic and clinical, is bringing us closer to more effective treatments and possibly even a cure.
Journal of the Dermatology Nurses’ Association · 2022 · 1 citations
Epidermolysis Bullosa Simplex
AbstractABSTRACT Epidermolysis bullosa simplex (EBS) is a rare autosomal dominant, genetic condition where bullous lesions, larger than 0.5 cm, affect an area of the skin that is exposed to mechanical friction or minor trauma. Prevention of the bullous lesions starts with family and patient education, with infants requiring greater care and control of their environment. Every individual with EBS will have a treatment plan specifically tailored to the severity and extent of skin involvement. This article provides a comprehensive overview of EBS, including diagnostic approach, preventative considerations, and current treatments.
Progressive dysphagia in a young woman: An atypical presentation and late diagnosis of epidermolysis bullosa.
AbstractIntroduction: Epidermolysis bullosa (EB) is a rare and phenotypically heterogeneous group of inherited connective tissue disorders. The most prominent feature is skin that easily blisters or tears from minor physical stress, though injury may extend to the mucous membranes. Symptoms range from mild to severe, and usually present shortly after birth or in early infancy. Though the majority of diagnoses are made in childhood, EB is an uncommonly encountered disease in the pediatric population as a whole, and even more uncommon in the adult population. Case: A 23-year-old female with …
Patterns of Oral Soft Tissue Lesions and Therapeutic Strategies in Children and Adolescents with Epidermolysis Bullosa: A Scoping Review
AbstractEpidermolysis bullosa (EB) is a group of rare genetic disorders characterized by extreme fragility of the skin and mucous membranes, leading to the formation of blisters and ulcers even after minimal trauma, thereby impairing functions such as feeding, speech, and mastication. Clinical forms include EB simplex, junctional EB, dystrophic EB, and Kindler syndrome, with oral manifestations primarily affecting the tongue, lips, and buccal mucosa. The aim of this scoping review was to map the patterns (type and location) of oral soft tissue lesions and identify therapeutic strategies described for children and adolescents with EB. The methodology followed the PRISMA Extension for Scoping Reviews guidelines and was registered on the Open Science Framework. Case reports and case series providing detailed clinical information on oral soft tissue lesions were included, with no restrictions regarding language or publication period. Studies addressing exclusively systemic manifestations or other oral conditions were excluded. The search was conducted in electronic databases and gray literature, and study selection was carried out in three stages—title screening, abstract screening, and full-text review—performed independently by two reviewers. Twenty studies were included, involving patients aged between 11 months and 18 years, with a higher frequency of lesions on the lips and tongue. The therapeutic strategies described included clinical approaches, such as laser photobiomodulation, as well as home-based therapies, including the use of topical corticosteroids, chlorhexidine, anesthetic ointments, and vitamin supplementation. In conclusion, despite the diversity of therapeutic approaches reported in the literature, gaps remain in the standardization of clinical protocols and in long-term evaluation, highlighting the need for controlled studies to support evidence-based clinical guidelines and to promote multidisciplinary care and improved quality of life for children and adolescents with epidermolysis bullosa.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
